Results
An analysis of a series of haploid laboratory yeast strains revealed significant intra-strain variability and unstable plasmid segregation. By combining classic chemical mutagenesis and selection a family of highly efficient Saccharomyces cerevisiae strains has been developed for the commercial production of biopharmaceutical products. When combined with a stable [1] , high copy number [2] , episomal expression vector system and a strong constitutive promoter, secreted recombinant protein expression titres in excess of 4 g/L were achieved (see Figure 1 ). Specific genetic modifications to the host were also introduced to increase product yield and control posttranslational modifications, such as proteolysis and glycosylation.
The expression vectors have been further enhanced to facilitate the stable co-expression of multiple proteins. When one of these proteins is a chaperone, the titre of coexpressed recombinant transferrin was increased 15-fold. The applicability of this system has been demonstrated with a wide range of heterologous proteins and is scalable from 10 mL shake flask to cGMP manufacture at high cell density fermentation (8,000 L) in a defined synthetic medium; designed to be integrated with cost-efficient downstream processing.
Conclusion
Significant intra-strain variability and unstable episomal plasmid systems have limited the usefulness of Saccharomyces cerevisiae as an industrial host for the production of biopharmaceuticals. However co-enhancement of the episomal vector system and the host strains is not only possible but has led to significant improvements in recombinant protein production. 
